Drug Profile

ODA 611

Alternative Names: Anti-PfGARP mAb; ODA-611

Latest Information Update: 29 Aug 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Rhode Island Hospital
Developer Ocean Biomedical; Ocean Sihoma
Class Antimalarials; Monoclonal antibodies
Mechanism of Action Protozoan protein modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Malaria

Most Recent Events

27 Aug 2024 Ocean Biomedical has patent protection Malaria therapeutic antibody targeting PfGARP
16 May 2024 Ocean Biomedical has patent protection for malaria therapeutic antibody discoveries
11 Jul 2023 Antimicrobial data from preclinical studies in Malaria released by Ocean Biomedical

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com